December 2007
RN;Dec2007, Vol. 70 Issue 12, p30
Academic Journal
The article focuses on a meta-analyis of rimonabant which revealed that the weight-loss drug increases the risk of depression and anxiety and can increase users' suicidal thoughts. The drug targets the endocannabinoid system of the brain, which helps trigger and reward food intake. Sanofi-Aventis has not been granted approval to sell the drug in the U.S. due to reports of psychiatric side effects.


Related Articles

  • The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents. Hyeon-Kyu Lee; Eun Bok Choi; Chwang Siek Pak // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p482 

    Since the discovery of rimonabant (Acomplia: 1), a large effort has been directed at the discovery of new, potent and selective CB1R antagonists that serve as anti obesity drugs. As a result, a number of compounds reached various stages of clinical trials by late 2008. However, the announcement...

  • Disappointment at rimonabant halt.  // Independent Nurse;11/3/2008, p4 

    The article reports on clinicians' disappointment on the suspension of the weight-loss drug rimonabant, issued by the European Medicines Agency (EMEA). It is stated that EMEA raised concerns about the risk of psychiatric disorders in patients treated with the drug, and warned no further...

  • Lorcaserin.  // Reactions Weekly;Dec2015, Vol. 1580 Issue 1, p236 

    The article describes the case of a 39-year-old male patient who experienced worsening depression after being treated with the weight-loss drug, lorcaserin.

  • Suicide fears over weight-loss drug.  // PRWeek (London);7/4/2008, p6 

    The article looks at the suicide concerns over the weight-loss drug Acomplia, manufactured by Sanofi-Aventis. The drug has been approved by the British National Institute for Health and Clinical Excellence (NICE) and it is licensed in the Great Britain for the treatment of obese and overweight...

  • Obesity Drug In the Wings.  // Nutrition Business Journal;Mar2005, Vol. 10 Issue 3, p10 

    Reports on French company Sanofi-Aventis' preparation for the launch of a weight loss drug called rimonabant, brand name Acomplia, in 2006. Drug's targeting of the endocannabinoid system in the brain, believed to play a role in regulating appetite; Estimated sales of the drug in the U.S. if it...

  • Sanofi-Aventis: safety concerns delay US approval for obesity drug.  // PharmaWatch: Monthly Review;Aug2007, Vol. 6 Issue 8, p10 

    The article reports on the failure of an advisory panel of the Food and Drug Administration (FDA) to endorse rimonabant under development by Sanofi-Aventis SA because of concerns over its safety profile. Depression and other psychiatric side effects have remained the biggest concern in studies...

  • Ambien hit with reports of sleep-eating. M. I. // Medical Marketing & Media;Apr2006, Vol. 41 Issue 4, p11 

    The article examines reports that link Sanofi-Aventis SA' Ambien (zolpidem) with episodes of sleepwalking and other side effects arising out of sleep in the United States. The reports discuss cases of Ambien patients bingeing on food and driving while in a semi-sleep state. In response,...

  • Weight-Loss Aid Alert. Calechman, Steve // Natural Health;Dec2002, Vol. 32 Issue 9, p24 

    Reports on the warning of U.S. Food and Drug Administration against using two Chinese weight-loss supplements Chasu Jianfei Diet Capsules and Chasu Gempi due to health problems in Japan.

  • Chinese slimming capsules poisoning people.  // Asian Pacific Post;4/16/2009, p10 

    The article reveals the side effects and serious health problems caused by Chinese slimming capsules available on the Internet.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics